2013-10-02 08:11:01 -
* Nicolai Wagtmann, previously Vice-President R&D at Novo Nordisk A/S,
generated and developed a portfolio of therapeutic antibodies for the
treatment of cancer and inflammatory diseases
* François Romagné to lead CIMTECH and join Innate Pharma's Scientific
Marseille, October 2, 2013
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the
innate immunity company developing first-in-class drug candidates for cancer and
inflammatory diseases, today announces the appointment of Nicolai Wagtmann as
Chief Scientific Officer. His appointment to the Executive Board will be
proposed at the next Supervisory board.
Nicolai Wagtmann joins Innate Pharma from Novo Nordisk A/S where he was Vice-
President R&D and Head of Inflammation Biology. Nicolai Wagtmann is a pioneer of
approaches targeting innate immunity lymphocytes both in immuno-
oncology and in inflammation. His research, initiated in academia, was developed
in industry through the research collaboration between Innate Pharma and Novo
Nicolai Wagtmann has resigned from Novo Nordisk A/S. His appointment as Innate
Pharma's CSO is independent of Innate Pharma's corporate agreement with Novo
Nordisk A/S and was supported unanimously by Innate Pharma's Supervisory board.
He replaces François Romagné, co-founder of Innate Pharma, Chief Scientific
Officer and member of the Executive Board since the Company's inception. From
January 2014 François Romagné will lead CIMTECH, the new immuno-technology
platform at Aix-Marseille University, which Innate Pharma co-founded. François
Romagné will join Innate Pharma's Scientific Advisory Board at the same date.
Nicolai Wagtmann said: "My team at Novo Nordisk has enjoyed very productive
interactions with Innate Pharma during a multi-year research collaboration which
resulted in three first-in-class therapeutic antibodies undergoing clinical
development. I have been impressed by Innate Pharma's unique scientific approach
for therapeutically modulating the immune system. I now look forward to leading
this excellent team to broaden and grow this unique platform and to advance
several novel drug candidates into clinical development over the next few years.
With the explosion of the immuno-pharmacoloy field, we have an exciting
opportunity for building a high-value therapeutic antibody company".
François Romagné said: "The appointment of Nicolai is a great opportunity for
Innate Pharma. Heading CIMTECH will allow me to focus on discovery and
validation of new targets in immunology, in close link with fundamental research
and of course Innate Pharma".
Hervé Brailly, CEO and co-founder of Innate Pharma, said: "We are very happy to
welcome Nicolai, who brings not only a deep understanding of immunology and its
creativity, but also an industrial vision which will be key for the growth and
development of Innate Pharma's portfolio of drug candidates.
François was decisive in building the Company and its portfolio of first-in-
class antibodies. The changes we are announcing today are an important step for
Innate Pharma and also for the structuring and development of Marseille-
Immunopole, confirming its world-class status as a collaborative ecosystem in
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approaches have led to licensing agreements with Novo
Nordisk A/S and Bristol-Myers Squibb.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 84 employees as at June 30, 2013.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
ISIN code FR0010331421
Ticker code IPH
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website ( www.amf-
france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.
For additional information, please contact:
Innate Pharma ATCG Press
Laure-Hélène Mercier Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87 Mob.: +33 (0)6 26 94 18 53
Appointment Nicolai Wagtmann:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INNATE PHARMA via Thomson Reuters ONE